Imugene Ltd (ASX:IMU, OTC:IUGNF) managing director and CEO Leslie Chong speaks with Proactive soon after announcing the first patient has been dosed in the combination cohort of the IMPRINTER study - a clinical trial to evaluate the safety and efficacy of Imugene’s PD1- Vaxx in combination with atezolizumab (Tecentriq®) in patients with non-small cell lung cancer. She says Tecentriq® has previously shown clinically meaningful benefit in various types of lung cancer, with six currently approved indications in the US.
Imugene doses first patient in PD1-Vaxx combination trial
